Exagen (XGN) Insider Frank Stokes Buys 37,500 Shares
Frank Stokes purchased 37,500 shares of XGN, joining recent insider activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Frank Stokes bought 37,500 shares of Exagen Inc. ($XGN) on June 9, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $XGN is up 5.6% after 1 week, up 7.2% after 1 month and up 79.1% to date (from the $4.31 close on Jun 9, 2026).
XGN
Exagen Inc.
Key Points
- Frank Stokes bought 37,500 shares of XGN on June 9, 2026, as the stock traded at $4.45.
- XGN has seen varied institutional interest, with some funds increasing and others reducing their holdings.
- Analysts have maintained a positive outlook, with several firms keeping a 'buy' rating on XGN.
Get $XGN trade alerts by text
We text you when insiders, Congress or big funds trade $XGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Exagen Inc. alert may contain errors. Disclosures
On June 9, 2026, Frank Stokes made a significant purchase of 37,500 shares of XGN. The transaction, which did not occur under a pre-planned trading program, adds to the recent insider activity around the company. XGN shares were trading near $4.45 on Monday.
Insider Buying and Selling at Exagen Inc.
Frank Stokes wasn't alone in his insider activity. Earlier this year, John Aballi, the President and CEO, acquired a total of 250,000 shares on March 12, 2026, at an average price of $3.16. Additionally, Jeffrey Black, the Chief Financial Officer, purchased 125,000 shares on the same date, also at $3.16 per share. These transactions reflect a continued insider interest in the company's stock.
Other Institutional Activity in XGN
There has been notable institutional movement in XGN recently. Balysany Asset Management L.P. reduced its holdings by 122,555 shares, bringing its total to 796,632 shares worth approximately $2.39 million. In contrast, Wexford Capital LP increased its position by 326,077 shares, ending with 792,855 shares valued at about $2.38 million. Acadian Asset Management LLC also boosted its holdings by 274,666 shares, resulting in 689,114 shares worth $2.06 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 678,652 shares valued at $2.04 million.
Analysts Set New Price Targets
Analysts have shown consistent confidence in XGN. On May 12, 2026, BTIG maintained its 'buy' rating with a price target of $8. Earlier, on April 20, Canaccord Genuity also upheld a 'buy' rating with the same target. Multiple firms, including Craig-Hallum and Keybanc, have similarly maintained 'buy' ratings, with targets reaching up to $10.
Bottom Line
The recent insider purchase by Frank Stokes adds to a series of acquisitions by company executives, suggesting confidence in XGN's future. Institutional investors show mixed actions, with some increasing and others decreasing their stakes. Analysts remain optimistic, maintaining 'buy' ratings with targets as high as $10. While insider transactions can be insightful, they are backward-looking and may not reflect current sentiment.
Related Filing Alerts
Source: Frank Stokes's Form 4 filing on $XGN (Jun 9, 2026). Find the original filing: XGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts